- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Pharmala Biotech Holdings Inc: Pharmala Biotech Australia hires CDMO for manufacturing | 1 | Stockwatch | ||
| 11.12. | Pharmala Biotech Holdings Inc: Pharmala completes release testing on LaNeo capsules | 1 | Stockwatch | ||
| 10.12. | PharmAla Biotech Completes Release Testing on Australian-Made LaNeo Capsules | 1 | GlobeNewswire (USA) | ||
| 04.11. | Pharmala Biotech Holdings Inc: Pharmala Biotech files final prospectus | 1 | Stockwatch | ||
| 03.11. | PharmAla Biotech: PharmAla Files Final Base Shelf Prospectus and Signs Term Sheet with Radium Capital | 204 | GlobeNewswire (Europe) | TORONTO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. ("PharmAla" or the "Company") (CSE: MDMA) (OTCQB:MDXXF), a biotechnology company focused on the research, development, and... ► Artikel lesen | |
| 09.10. | Pharmala Biotech Holdings Inc: Pharmala launches Nexus chain-of-care portal | 1 | Stockwatch | ||
| 08.10. | PharmAla Biotech: PharmAla Launches Nexus Portal for MDMA Prescribers and Therapists | 3 | GlobeNewswire (USA) | ||
| 02.10. | Pharmala Biotech Holdings Inc: Pharmala Biotech completes shipment to Johns Hopkins | 3 | Stockwatch | ||
| PHARMALA BIOTECH Aktie jetzt für 0€ handeln | |||||
| 02.10. | PharmAla Biotech: PharmAla Completes Shipment of LaNeo MDMA to Johns Hopkins | 2 | GlobeNewswire (USA) | ||
| 26.09. | Pharmala Biotech Holdings Inc: Pharmala enters distribution deal with Veridion | 3 | Stockwatch | ||
| 25.09. | PharmAla Biotech: PharmAla Partners with Veridion Group as Exclusive Distributor in New Zealand | 1 | GlobeNewswire (USA) | ||
| 19.09. | Pharmala Biotech Holdings Inc: Pharmala Biotech files amended preliminary prospectus | 1 | Stockwatch | ||
| 19.09. | PharmAla Biotech: PharmAla Files Amended and Restated Preliminary Base Shelf Prospectus | 1 | GlobeNewswire (USA) | ||
| 08.09. | PharmAla Biotech: PharmAla Completes Import of LaNeo MDMA for US Distribution | 92 | GlobeNewswire (Europe) | TORONTO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. ("PharmAla" or the "Company") (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and... ► Artikel lesen | |
| 04.09. | Pharmala Biotech Holdings Inc: Pharmala incorporates Ausi unit for clinical research | 2 | Stockwatch | ||
| 03.09. | PharmAla Biotech: PharmAla Incorporates Australian Entity for Clinical Research | 1 | GlobeNewswire (USA) | ||
| 08.08. | Pharmala Biotech Holdings Inc: Pharmala delivers 500 capsules of MDMA to Merhavim | 2 | Stockwatch | ||
| 07.08. | PharmAla Biotech: PharmAla Delivers MDMA to Merhavim Mental Health Centre Clinical Trial in Exchange for Full Data License | 1 | GlobeNewswire (USA) | ||
| 26.07. | Pharmala Biotech Holdings Inc: Pharmala omits Q3 net P&L in NR, talks expenses | 2 | Stockwatch | ||
| 25.07. | PharmAla Biotech: PharmAla Issues Q3 Financial Statements | 662 | GlobeNewswire (Europe) | TORONTO, July 25, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. ("PharmAla" or the "Company") (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and... ► Artikel lesen |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NURIX THERAPEUTICS | 18,520 | +2,83 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors | SAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of... ► Artikel lesen | |
| DISC MEDICINE | 80,04 | -11,50 % | Stifel reaffirms Buy rating on Disc Medicine stock amid FDA review speculation | ||
| DYNE THERAPEUTICS | 19,850 | +7,01 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares | WALTHAM, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 5,490 | +0,73 % | Citizens reiterates Market Outperform rating on Taysha Gene Therapies stock | ||
| SUMMIT THERAPEUTICS | 17,820 | +4,52 % | Summit Therapeutics stock rating reiterated by Cantor Fitzgerald | ||
| IMMUNEERING | 5,650 | -0,35 % | Immuneering Corporation: Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA | - End-of-Phase 2 interactions with FDA complete; scientific advice received from EMA - - Company expects to dose first patient in global Phase 3 registrational trial, MAPKeeper 301, in mid-2026 -... ► Artikel lesen | |
| RELAY THERAPEUTICS | 8,400 | +3,32 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025 | Efficacy data remain consistent with previous disclosures, showing 10.3-month median PFS in all patients and 11.4-month median PFS in 2L patients Subset analyses show broad activity in patients with... ► Artikel lesen | |
| SANA BIOTECHNOLOGY | 4,360 | -3,11 % | Sana Biotechnology, Inc: Sana Biotechnology Announces Positive Six-Month Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression | Groundbreaking First-in-Human Study Establishes Potential to Treat Type 1 Diabetes by Transplanting Insulin-Secreting Cells Without Immunosuppression Six-Month Patient Follow-up Results Demonstrate... ► Artikel lesen | |
| QIAGEN | 38,740 | +0,77 % | QIAGEN N.V.: QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $500 Million | Return of approximately $500 million maximum approved by shareholders set to be completed on January 7, 2026 Capital return to be conducted through synthetic share repurchase combines a... ► Artikel lesen | |
| TREVI THERAPEUTICS | 13,010 | +6,73 % | Potenzial von Hustenmedikament: Stifel erhöht Kursziel für Trevi Therapeutics auf 18 Dollar | ||
| VIR BIOTECHNOLOGY | 5,760 | -2,87 % | EQS-News: Norgine Pharmaceuticals Limited: Norgine erweitert sein Hepatologie- und Spezialitätenportfolio durch exklusive Einlizenzierungsvereinbarung mit Vir Biotechnology | EQS-News: Norgine Pharmaceuticals Limited
/ Schlagwort(e): Produkteinführung/Vereinbarung
Norgine erweitert sein Hepatologie- und Spezialitätenportfolio durch exklusive Einlizenzierungsvereinbarung... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,32 | +0,26 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| ABSCI | 3,380 | -0,88 % | Absci Partners With Oracle And AMD To Accelerate AI-Driven Drug Discovery | SUNNYVALE (dpa-AFX) - Absci, a clinical-stage biotech focused on AI-powered therapeutics, announced a collaboration with Oracle Cloud Infrastructure - OCI and Advanced Micro Devices, Inc. (AMD)... ► Artikel lesen | |
| VOR BIOPHARMA | 12,410 | -3,05 % | Vor Biopharma Inc. - 8-K, Current Report | ||
| ARVINAS | 11,680 | +3,55 % | Arvinas Inc.: Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders | - ARV-102 was well tolerated in clinical trials for both healthy volunteers and patients with Parkinson's disease - - ARV-102 demonstrated dose-dependent cerebrospinal fluid (CSF) exposure in subjects... ► Artikel lesen |
PHARMALA BIOTECH HOLDINGS INC gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PHARMALA BIOTECH HOLDINGS INC finden Sie auf Wallstreet Online.